Dehlia Moore

Dehlia Moore supports the Centers for Disease Control and Prevention’s Office of Acquisition Services in securing critical goods and services that advance public health infrastructure. She manages complex procurement actions focused on laboratory diagnostics, biomedical research tools, and data-driven surveillance systems essential to CDC’s mission of disease detection and rapid response. Her work ensures timely access to high-integrity scientific equipment, in-vitro diagnostic reagents, and analytical instrumentation used in national health monitoring and outbreak response operations, aligning procurement strategy with federal health security priorities. Moore maintains established relationships with key contractors including General Dynamics Information Technology, Cepheid, GlaxoSmithKline, MRIGLOBAL, and the New York City Health & Hospitals Corp. These partnerships reflect a preference for industry leaders with proven capabilities in clinical diagnostics, biotechnology R&D, and large-scale public health service delivery. Her contracting approach emphasizes technical compliance, regulatory alignment with FDA and CLIA standards, and performance-based acquisition methods to ensure reliability and scalability of delivered solutions across federal and state health networks. Her procurement patterns show a strong preference for full and open competition, with 96% of awards issued without set-asides, indicating a focus on technical excellence and mission-critical capability over socioeconomic preferences. Only 4% of awards are structured as total small business set-asides under FAR 19.5, suggesting a targeted, rather than broad, commitment to small business participation—typically reserved for niche or specialized technical services where qualified small vendors demonstrate unique expertise. Her primary procurement focus lies in NAICS 811219 (other commercial and industrial machinery repair), 334516 (analytical laboratory instrument manufacturing), and 541714 (biotechnology R&D), reflecting deep engagement with precision diagnostic equipment, lab automation systems, and advanced bioscience research tools. She consistently procures high-complexity items including PCR platforms, genomic sequencing systems, and clinical assay kits, demonstrating specialized expertise in the intersection of public health science and federal acquisition regulation.